A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Chronic Hepatitis C Clinical Trial

Official title:

An Open-label, Randomized, 5-arm, Parallel-group Study of the Effects on Viral Kinetics, Safety and Pharmacokinetics of Different Dosing Regimens of Debio 025 in Combination With Peginterferon Alpha-2a and Ribavirin in Chronic HCV Genotype 1 Patients Who Are Non Responders to Standard Peginterferon Alpha and Ribavirin Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00537407
• Other study ID #: Debio 025-HCV-207
• Secondary ID: DEB025A2207
• Status: Completed
• Phase: Phase 2
• First received: September 28, 2007
• Last updated: February 12, 2016
• Start date: September 2007
• Est. completion date: April 2010

Study information

• Verified date: February 2016
• Source: Debiopharm International SA
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Debio 025 (alisporivir) is an oral cyclophilin inhibitor with a new mechanism of action demonstrating potent anti-hepatitis C virus (HCV) activity in pre-clinical models and patients.

The current standard of care (SOC) in HCV patients consists of a combination of peg-IFN alpha and ribavirin. Treatment duration and ribavirin dose depend on the genotype treated. Only 40-50% of patients with genotype 1 achieve a sustained viral response (SVR). This study assesses whether Debio 025 administered in combination with peg-IFN alpha 2a and ribavirin can improve the outcome of treatment in this group of patients.

Description:

This is a multicentre, open-label, randomized, 5 arm parallel-group, multiple dose study in 50 chronic hepatitis C virus (HCV) genotype 1 non-responders to standard treatment with peg-IFN alpha (2a or 2b) and ribavirin. The entire study lasts a maximum of 96 weeks and consists of a 48- or 72-week treatment period (according to response). A follow-up visit to assess the sustained viral response (SVR) takes place 24 weeks after treatment cessation, i.e., at study Week 72 or 96, or earlier for discontinued study participants.

There were 2 parts in the treatment period. Part 1 lasted from Day 1 to Day 29 (Weeks 1 to 4); Part 2 lasted from Week 5 to Week 48 or 72.

During Part 1 of treatment (Weeks 1 to 4), participants are randomized to 1 of 5 treatment arms and receive 4 weeks of Debio 025 (alisporivir) monotherapy, Debio 025 combined with standard dose peg-IFNα2a, or 1 of 3 triple therapies combining different doses of Debio 025 with peg-IFNα2a and ribavirin at standard doses.

During Part 2 of treatment (Weeks 5 to 48 or 72), participants receive standard doses of peg-IFNα2a/ribavirin dual therapy for 44 or 68 weeks, depending on their response to treatment. At Week 12, participants who do not achieve ≥ 2 log10 decrease in HCV RNA are withdrawn and considered treatment failures. Participants who have undetectable HCV RNA levels and/or ≥ 2 log10 decrease in HCV RNA continue treatment until Week 24. At Week 24, participants who still have detectable HCV RNA levels are withdrawn and considered treatment failures. Participants with undetectable HCV RNA levels at Weeks 12 and 24 continue treatment until Week 48. At Week 24, "slow responders" (defined as participants with a detectable, but > 2 log10 decrease in HCV RNA levels at Week 12 and undetectable levels at Week 24) are eligible to continue treatment until Week 72.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: April 2010
• Est. primary completion date: April 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Male and female patients between 18 and 60 years of age.

• Hepatitis B negative and human immunodeficiency virus (HIV) negative.

• Diagnosed with hepatitis C genotype I and not responsive to treatments such as peginterferon alpha-2a or 2b and ribavirin for at least 12 weeks.

• Adequate liver function (Child-Pugh-Turcotte score A) and other laboratory parameters within acceptable range.

• Females may participate only if they cannot become pregnant, i.e., are surgically sterile, post-menopausal, or using 2 reliable contraceptive methods.

• Male patients must be surgically sterile or utilizing a barrier contraceptive method.

• For female patients of child bearing potential, negative pregnancy test within 1 week of first investigational product administration.

Exclusion Criteria:

• Treatment with any investigational drug within 6 months prior to the start of the study.

• Ongoing or recent use of antiviral medication within 1 month before the start of the study.

• A known bad reaction or intolerance to Debio 025, peginterferon alpha-2a, and/or ribavirin.

• Presence or history of any severe related disease.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Hepatitis C
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• Debio 025
Debio 025 supplied as a 100 mg/mL oral solution
• Peg-IFNa2a
Peg-IFNa2a supplied in 180 µg/0.5 mL prefilled syringes
• Ribavirin
Ribavirin supplied as 200 mg tablets

Locations

Country	Name	City	State
United States	The Johns Hopkins University School of Medicine	Baltimore	Maryland
United States	Methodist Transplant Physicians	Dallas	Texas
United States	Metropolitan Research	Fairfax	Virginia
United States	University of Florida	Gainesville	Florida
United States	Scripps Clinic Liver Disease Research Center	la Jolla	California
United States	University of Miami Center for Liver Diseases	Miami	Florida
United States	Virginia Mason Medical Center	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Debiopharm International SA

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Triple Therapy Treatment Arms (A, D, and E)	Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction.	Baseline to Day 29	No
Secondary	Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Monotherapy and Dual Therapy Treatment Arms (B and C)	Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction.	Baseline to Day 29	No
Secondary	log10 Hepatitis C Virus RNA at Day 29	Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction.	Day 29	No
Secondary	Percentage of Participants With a Rapid Viral Response at Day 29	A participant had a rapid viral response if their viral RNA was undetectable (< 10 IU/mL).	Day 29	No
Secondary	Percentage of Participants With an Early Viral Response at Week 12	A participant had an early viral response if their viral RNA had decreased = 2 log10 at Week 12 compared to Baseline.	Baseline to Week 12	No
Secondary	Percentage of Participants With an End-of-treatment Response at the End of Treatment (Week 48 or 72)	A participant had an end-of-treatment response if their viral RNA was undetectable (< 10 IU/mL).	End of treatment (Week 48 or 72)	No
Secondary	Percentage of Participants With a Sustained Viral Response 24 Weeks After the End of Treatment (Week 72 or 96)	A participant had a sustained viral response if their viral RNA was undetectable (< 10 IU/mL).	24 weeks after the end of treatment (Week 72 or 96)	No